Pfizer breaks $28.50 support as pharma sector falls nearly 2%
Pfizer broke below $28.50 support as the pharma sector fell nearly 2%. FxPro sees $27.00 next, with a daily close above $29.75 canceling its bearish setup.
By Grace Kim
3 min read

What's News
- Pfizer broke below $28.50 support, a level marked by a 38.2% Fibonacci correction and an August daily uptrend line.
- The pharmaceutical sector fell nearly 2% today on a Merck pipeline setback and U.S. drug-pricing scrutiny.
- FxPro set $27.00 as the next support and target for completing correction 2.
- Pfizer's $2.6bn early-stage CAR-T licensing deal was announced yesterday.
- A daily close above $29.75, the top of wave b, would cancel the bearish scenario.
By Grace Kim
Pfizer Inc. broke below $28.50 support while the pharmaceutical sector fell nearly 2%, according to FxPro's technical analysis of BATS:PFE. FxPro attributed the sector decline to a Merck pipeline setback and ongoing U.S. drug-pricing scrutiny.
What made $28.50 a pivotal level?
FxPro identified $28.50 as a support zone marked by two technical anchors: the 38.2% Fibonacci correction of the upward impulse from the start of July and the daily uptrend line from August.
The level also has a layered history in Pfizer's chart. It capped the stock at the start of April, turned into support after the breakout in October, and stopped wave a earlier this month, FxPro said.
That sequence gives the breakdown a wider technical context. FxPro viewed the July impulse and the trendline from August as separate markers that converged at $28.50.
The break also accelerated the active wave c of an ABC correction 2 that began at the start of November, according to FxPro. In its framework, wave c sat within the larger correction, and the loss of $28.50 accelerated that wave.
Takeaway: FxPro says Pfizer lost the $28.50 zone, where a Fibonacci level and a daily trendline met.
Why didn't the $2.6bn CAR-T deal support Pfizer?
Pfizer announced a $2.6bn licensing deal for early-stage CAR-T programmes yesterday, FxPro said. Despite the size of the transaction, it did little to support Pfizer shares.
The muted response came as the pharmaceutical sector fell nearly 2% today. FxPro said Merck's pipeline setback and continuing U.S. drug-pricing scrutiny were weighing on the group, keeping broad sentiment bearish across large-cap pharma stocks.
The sector move supplied the immediate backdrop for the chart. The licensing announcement supplied the main company-specific development, but FxPro said it did little to support the stock.
Takeaway: FxPro says the $2.6bn deal provided little support amid a nearly 2% sector decline.
Where does the next downside target sit?
FxPro set $27.00 as Pfizer's next support level and the target price for completing the active correction 2. The target extended the technical map beyond the broken $28.50 zone.
The $27.00 level stopped the previous correction (2) at the start of October, FxPro said. It also stands just below the 50% Fibonacci correction, placing another chart reference close to the projected downside target.
FxPro therefore viewed $27.00 as a confluence of a prior correction stop, a Fibonacci marker and the current correction target. The active wave c was accelerating below $28.50 as the stock approached that cluster.
At $27.00, the projected move would complete the active correction 2, according to FxPro. The level would serve as both the target and the next support test.
Takeaway: $27.00 is both FxPro's next support and its target for completing correction 2.
What would end the bearish setup?
FxPro's condition for a reversal was straightforward: "If 27.00 holds, the correction 2 is likely to end there and Pfizer can resume its uptrend toward 28.50."
A daily close above $29.75 would cancel the bearish scenario, FxPro said. The $29.75 threshold marks the top of wave b.
The note's near-term verdict was blunt: "In the near term, sellers keep control below 28.50." In FxPro's view, sellers retain control while Pfizer remains under the broken support zone.
For now, FxPro's setup puts $27.00 under immediate scrutiny on the downside and a daily close above $29.75 on the upside as the condition for breaking the bearish case.
Source: tradingview.com
More from Grace Kim
Show full bio
Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.
2,454 articles